Stanford researchers have developed antisense oligonucleotides (ASOs) that selectively block pathological cryptic exon inclusions in key neuronal genes to treat TDP-43-related neurodegenerative diseases.
KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Researchers from Stanford University and the Technical University of Munich (TUM) propose a new approach for treating Type 2 Diabetes (T2D) by targeting the cathelicidin gene expression pathway.
Huntington's Disease and other ataxias are devastating diseases without any cure or treatment. They are caused by the formation of toxic oligomeric and the aggregation of the Huntintin (HTT) protein.
Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Stanford scientists have discovered novel high molecular weight isoforms of thymic stromal lymphopoietin (TSLP), measured using nanoimmunoassay (NIA), that can serve as a blood-based biomarker for the diagnosis and prognostication of acute graft versus host disease (aGVHD).
Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.
Researchers from Stanford have developed a novel topical pharmaceutical composition comprising of a chemical inhibitor encapsulated in nanomicelles for the treatment of vision loss associated with acute optic neuropathies.
Researchers at Stanford, in collaboration with UCSF, have developed a two-part approach to preventing preterm birth (PTB), the leading cause of infant mortality worldwide. Current treatments, like low-dose aspirin and progesterone, are limited and often ineffective.
Researchers at Stanford have created the first small primate model to study human heart rhythm disorders and also discovered a new way the heart keeps its beat.
Stanford scientists have developed Q-DOAS (Quantitative Detection of Oligomer and Amyloid Seeds), a plate reader-based fluorescence quenching assay designed to track the formation of early-stage toxic oligomers and amyloid seeds in real-time.
Over 1 in 3 people are affected by neurological conditions worldwide. Pharmacological and surgical treatment options may be limited due to access, side effects, and reduced therapeutic efficacy.